FcGR1a (CD64) Knockout THP-1 Cell Line

Products from BPS Bioscience require a minimum order value above 400€

Applications:

• Study phenotype changes related to FcGR1a (CD64) knockout.
• Introduce further CRISPR/Cas9-based genetic manipulations to understand the interplay between FcGR1a (CD64) and other partners and pathways.
• Use as negative control in experiments involving CD64 related ADCC.

Background: FcGR1a (Fc Gamma Receptor Ia), also known as CD64, is a 72 kDa transmembrane glycoprotein that with CD32 and CD16 receptors form the large immunoglobulin superfamily. This protein is a high-affinity Fc-gamma receptor and plays an important role in both innate and adaptive immune responses. It can be found in monocytes, macrophages, and dendritic cells (DCs), but is absent in neutrophils under normal conditions. During infection the expression of FcGR1 is quickly increased in neutrophils, clustering in the cell membrane and allowing rapid binding and internalization of immune complexes. It mediates IgG effector functions in macrophages, triggering antibody-dependent cellular cytotoxicity (ADCC) of virus-infected cells and clearance of immune complexes. Diseases associated with FcGR1a include peritonitis and pharyngitis, but it is also linked to AML (acute monocytic leukemia) subtypes M4 and M5. Among its related pathways are ADORA2B (adenosine A2B receptor)-mediated anti-inflammatory cytokine production and regulation of actin dynamics for phagocytic cup formation. FcGR1a has been studied in the treatment of diseases related to macrophage-mediated chronic inflammation, such as rheumatoid arthritis (RA) and chronic diabetic wounds (CDW), and AML. Recently, fusion proteins made of CD64/CD16A have been used to create armed iPSC derived NK cells, resulting in sustained and robust ADCC in a mouse model. The use of FcGR1a-directed immunotoxins or cytolytic fusion proteins may open new avenues of treatment in multiple diseases linked to this protein.

Description: FcGR1a (CD64) Knockout THP-1 Cell Line is a THP-1 cell line in which FcGR1a (Fc Gamma Receptor Ia or CD64) has been genetically removed from THP-1 cells using CRISPR/Cas9 genome editing with a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human FcGR1a (CD64).

Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.

Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

Supplied As: Each vial contains ~1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Uniprot: P12314

Warnings: Avoid freeze/thaw cycles

Biosafety Level: BSL-1

References: Xu J. and Guo Y., 2020 Front Mol Biosci 7:581615.
Akinrinmade O., et al., 2017 Biomedicines 5(3): 56.

• Artikelnummer: BPS82191
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 82191
• Verpackungseinheit: 2 vials
• Mengeneinheit: PAK